Intravesical bacillus calmette–guérin treatment for t1 high‐grade non‐muscle invasive bladder cancer with divergent differentiation or variant morphologies

Abstract

The 2016 World Health Organization classification newly described infiltrating urothelial carcinoma (UC) with divergent differentiation (DD) or variant morphologies (VMs). Data comparing oncological outcomes after bladder‐preservation therapy using intravesical Bacillus Calmette– Guérin (BCG) treatment among T1 bladder pure UC (pUC), UC with DD (UC‐DD), and UC with VMs (UC‐VM) are limited. We evaluated 1490 patients with T1 high‐grade bladder UC who re-ceived intravesical BCG during 2000–2019. They were classified into three groups: 93.6% with pUC, 4.4% with UC‐DD, and 2.0% with UC‐VM. Recurrence‐free, progression‐free, and cancer‐specific survival following intravesical BCG were compared among the groups using multivariate Cox regression analysis, also used to estimate inverse probability of treatment weighting‐adjusted hazard ratio and 95% confidence interval for the outcomes. Glandular differentiation and micropapillary variant were the most common forms in the UC‐DD and UC‐VM groups, respectively. Of 1490 pa-tients, 31% and 13% experienced recurrence and progression, respectively, and 5.0% died of bladder cancer. Survival analyses revealed the impact of concomitant VMs was significant for cancer‐specific survival, but not recurrence‐free and progression‐free survival compared with that of pUC. Our analysis clearly demonstrated that concomitant VMs were associated with aggressive behavior in contrast to concomitant DD in patients treated with intravesical BCG.